Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824649 · ClinicalTrials.gov registry record · Phase 4
Biologics in Chronic Rhinosinusitis With Nasal Polyposis
A Phase 4 study, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 504
- Enrollment target
NCT06824649 is a Phase 4 study that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 504 participants.
The verdict
NCT06824649, a Phase 4 study, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 504 participants
- Enrollment target
Study Summary
The prevalence of Chronic Sinusitis with Nasal Polyps (CRSwNP) in the United States is estimated at roughly 4%, which equates to over 13 million Americans. Until recently, the only medical treatment options available for patients with CRSwNP were corticosteroids, with surgery reserved for medical failure. The development of biologic medications over the last 5 years has revolutionized the treatment of CRSwNP. Three biologic medications have been FDA approved and available for the treatment of CRSwNP: dupilumab, omalizumab, and mepolizumab. However, data from the clinical trials for these drugs do not show universal improvement across all patients with CRSwNP. In fact, there is a wide range of outcomes for patients in these trials. The result is that clinicians have no way of knowing which specific biologic would be the best option for any given patient, nor do they know whether biomarkers can be used to predict response to biologics. It is hoped that findings from this study will inform whether any one biologic has superior outcomes to another and whether clinicians can identify patients at baseline who are most likely to improve on biologic therapy.
Interventions
- BIOLOGICAL Biologic Agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 504 participants |
| Start Date | 2026-06-03 |
| Est. Completion | 2030-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06824649
The ClinicalTrials.gov registry entry for NCT06824649 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biologic Agents is the first listed.
NCT06824649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06824649 about?
NCT06824649 is a clinical study titled "Biologics in Chronic Rhinosinusitis With Nasal Polyposis". The prevalence of Chronic Sinusitis with Nasal Polyps (CRSwNP) in the United States is estimated at roughly 4%, which equates to over 13 million Americans. Until recently, the only medical treatment options available for patients with CRSwNP were corticosteroids, with surgery reserved for medical fa...
What is the current status of trial NCT06824649?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 504 participants. The study started on 2026-06-03. Estimated completion is 2030-02.
What interventions are being tested in trial NCT06824649?
The interventions under investigation include: Biologic Agents (BIOLOGICAL).
Who is sponsoring clinical trial NCT06824649?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.